Your browser doesn't support javascript.
loading
[Survival analysis of unexpected small cell lung cancer following surgery].
Guo, J T; Shen, L L; Liang, C Y; Liu, X; Zhang, T; Ma, Y F; Liu, Y.
Afiliação
  • Guo JT; Department of Thoracic Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
  • Shen LL; Department of Thoracic Surgery, Hainan Hospital, Chinese PLA General Hospital, Sanya 572000, China.
  • Liang CY; Department of Thoracic Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
  • Liu X; Department of Thoracic Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
  • Zhang T; Department of Thoracic Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
  • Ma YF; Department of Thoracic Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
  • Liu Y; Department of Thoracic Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
Zhonghua Zhong Liu Za Zhi ; 44(6): 550-554, 2022 Jun 23.
Article em Zh | MEDLINE | ID: mdl-35754229
ABSTRACT

Objective:

To investigate the survival and influencing factors of unexpected small cell lung cancer following surgery.

Methods:

We respectively reviewed the clinical characters of 104 patients who underwent surgical treatment and be proved as small cell lung cancer by pathology between January 2000 to October 2020 in Chinese PLA General Hospital. Overall survival (OS) of patients was evaluated using Kaplan-Meier and Cox proportional hazards analysis.

Results:

Of 104 patients, 27 cases showed central lesions, and other 77 showed peripheral nodules. The margin of nodules was smooth in 42 cases on CT imaging. The median OS was 34.3 months and 5-year OS rate was 45.8%. Postoperative 5-year OS rates for patients were 52.1%, 45.4%, and 27.8% for clinical stages Ⅰ, Ⅱ, and Ⅲ, respectively. Univariate analyses identified the age, surgical access, surgical approach, N stage, TNM stage and vascular cancer emboli were associated with OS (P<0.05). The N stage was an independent factor for the OS of patients (P<0.05).

Conclusions:

Patients with unexpected SCLC, including Ⅰ, Ⅱ and part ⅢA stage have favorable outcome and can benefit from surgery and systemic postoperative treatment. Standard lobectomy plus systemic lymph node dissection is commended.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Pequenas Células do Pulmão / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: Zh Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Pequenas Células do Pulmão / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: Zh Ano de publicação: 2022 Tipo de documento: Article